Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084524 | 0.86 | MET (0.44) | METKDRRETKITPDGFRA | |
| SCHEMBL26034059 | 0.83 | MET (0.65) | METKDRRETKITPDGFRA | |
| SCHEMBL30495869 | 0.82 | MET (0.53) | METKDRRETKITPDGFRA | |
| SCHEMBL14742895 | 0.82 | MET (0.53) | METKDRRETKITPDGFRA | |
| SCHEMBL17183536 | 0.81 | PARP10 (0.46) | METCYP3A4AXL | |
| SCHEMBL28115832 | 0.78 | PLK4 (0.38) | METKDRKIT | |
| SCHEMBL14771282 | 0.76 | MET (0.41) | METKDRRETKITPDGFRA | |
| SCHEMBL28360056 | 0.76 | MET (0.45) | METKDRRETKITPDGFRA | |
| SCHEMBL24297142 | 0.76 | MET (0.41) | METKDRRETKITPDGFRA | |
| SCHEMBL22249521 | 0.75 | MET (0.43) | METKDRRETKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595273-B2 | Phosphonate conjugates and uses thereof | TRANSLATIONAL GENOMICS RES INST (US) | 2026-04-07 | — | — | US | disclosed |
| EP-3719012-B1 | N-[4-[(2-AMINO-4-PYRIDINYL)OXY]-3-FLUOROPHENYL]-3-(4-FLUOROPHENYL)-1,2,3,4-TETRAHYDRO-2,4-DIOXO-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AS C-MET/AXL INHIBITORS FOR THE TREATMENT OF TUMORS | MEDSHINE DISCOVERY INC (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20220119425-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | UNITED STATES GOVERNMENT | 2022-04-21 | — | — | US | disclosed |
| US-20210371395-A1 | URACIL COMPOUND AS C-MET/AXL INHIBITOR | MEDSHINE DISCOVERY, INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3911320-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | The Translational Genomics Research Institute (US) | 2021-11-24 | — | — | EP | disclosed |
| US-7851489-B2 | Pyridinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2235001-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | Bristol-Myers Squibb Company (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-2089364-A1 | PYRIDINONE COMPOUNDS | Brystol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008058229-A1 | PYRIDINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008058229-A1 | PYRIDINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, MET, AXL | MET 2/4885KDR 55/4885RET 5/4885 |
| US-20210371395-A1 | URACIL COMPOUND AS C-MET/AXL INHIBITOR | AXL, MET, FLT3 | MET 2/4885KDR 65/4885RET 7/4885 |
| US-20220119425-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | ACP1, PTMS, RET | MET 53/4885KDR 205/4885RET 3/4885 |
| US-12595273-B2 | Phosphonate conjugates and uses thereof | RET, PTK2, ERBB2 | MET 46/4885KDR 261/4885RET 1/4885 |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | MET, HGF, DCK | MET 1/4885KDR 147/4885RET 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.